Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sofosbuvir plus ribavirin in chronic genotype 2 or 3 hepatitis C
NL-OMON39204Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sofosbuvir and ribavirin in chronic hepatitis C (CHC) (3 arms), sponsored by Gilead Sciences. Primary endpoints: SVR12 and Safety and tolerability. Started Nov 2012; status: active, not recruiting.
02
Drugs
sofosbuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NL-OMON39204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39204.